Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3809238 | 1.00 | NOS1 (0.33) | NOS1KMT2AMEN1GAANOS3 | |
| SCHEMBL6932447 | 0.89 | KMT2A (0.36) | NOS1KMT2AMEN1GAANOS3 | |
| SCHEMBL6230762 | 0.84 | MEN1 (0.35) | NOS1KMT2AMEN1GAANOS3 | |
| SCHEMBL3671404 | 0.84 | MEN1 (0.35) | NOS1KMT2AMEN1GAANOS3 | |
| SCHEMBL28739490 | 0.84 | MEN1 (0.35) | NOS1KMT2AMEN1GAANOS3 | |
| SCHEMBL3622338 | 0.84 | MEN1 (0.35) | NOS1KMT2AMEN1GAANOS3 | |
| SCHEMBL12742954 | 0.83 | GABRR1 (0.32) | NOS1NOS3NOS2LMNA | |
| SCHEMBL38661123 | 0.83 | CA2 (0.38) | NOS1KMT2AMEN1GAANOS3 | |
| SCHEMBL8329644 | 0.82 | NOS1 (0.33) | NOS1KMT2AMEN1GAANOS3 | |
| SCHEMBL28058283 | 0.82 | KMT2A (0.36) | NOS1KMT2AMEN1GAANOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| CN-101466725-B | Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders | SIGMA TAU IND FARMACEUTI | 2014-06-25 | — | — | CN | disclosed |
| CN-101671218-B | Alcohol production method by reducing ester or lactone with hydrogen | TAKASAGO PERFUMERY CO LTD | 2014-06-18 | — | — | CN | disclosed |
| US-8524953-B2 | Alcohol production method by reducing ester or lactone with hydrogen | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2161251-B1 | Alcohol production method by reducing ester or lactone with hydrogen | TAKASAGO PERFUMERY CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20130006020-A1 | ALCOHOL PRODUCTION METHOD BY REDUCING ESTER OR LACTONE WITH HYDROGEN | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-01-03 | — | — | US | disclosed |
| US-8288575-B2 | Alcohol production method by reducing ester of lactone with hydrogen | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-10-16 | — | — | US | disclosed |
| CN-101511359-B | Benzotriazole kinase modulators | HOFFMANN LA ROCHE | 2012-09-05 | — | — | CN | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| CN-101671218-A | Alcohol production method by reducing ester or lactone with hydrogen | TAKASAGO PERFUMERY CO LTD | 2010-03-17 | — | — | CN | disclosed |
| EP-2066319-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| WO-2008028860-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
| CN-1054846-C | Use of intermediates for production of aromatic aminoalcohol derivatives having anti-diabetic and anti-obesity properties | SANKYO CO (JP) | 2000-07-26 | — | — | CN | disclosed |
| CN-1036588-C | Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO CO (JP) | 1997-12-03 | — | — | CN | disclosed |
| CN-1151401-A | Use of intermediates for production of aromatic aminoalcohol derivatives having anti-diabetic and anti-obesity properties | SANKYO CO (JP) | 1997-06-11 | — | — | CN | disclosed |
| CN-1034497-C | Process for the preparation of aromatic aminoalcohol derivatives useful for the treatment of diabetes and obesity | SANKYO CO (JP) | 1997-04-09 | — | — | CN | disclosed |
| CN-1033750-C | Intermediate compounds for the preparation of aromatic amino alcohol derivatives having anti-diabetic and anti-obesity properties | SANKYO CO (JP) | 1997-01-08 | — | — | CN | disclosed |
| CN-1106396-A | Intermediate compounds for the preparation of aromatic amino alcohol derivatives having anti-diabetic and anti-obesity properties | SANKYO CO (JP) | 1995-08-09 | — | — | CN | disclosed |
| CN-1073428-A | Aromatic amino alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic use | SANKYO CO (JP) | 1993-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130006020-A1 | ALCOHOL PRODUCTION METHOD BY REDUCING ESTER OR LACTONE WITH HYDROGEN | ADH1A, ADH1C, ADH5 | NOS1 292/4885KMT2A 3104/4885MEN1 491/4885 |
| US-20080103142-A1 | Benzotriazole kinase modulators | CDK1, CDK3, MAPK1 | NOS1 2415/4885KMT2A 473/4885MEN1 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.